Astex Pharmaceuticals Email Format

Biotechnology ResearchEngland, United Kingdom51-200 Employees

Astex Pharmaceuticals is a biotechnology research company focused on discovering new medicines for cancer and central nervous system disorders. It advances candidate compounds through an in-house fragment-based drug discovery approach, with several programs moving into clinical development. Through collaborations with major pharmaceutical partners, the company has contributed to the development and market entry of three oncology drugs: Kisqali (with Novartis), Balversa (with Janssen), and Truqap (from AstraZeneca). The firm is based in Cambridge, England, at the Cambridge Science Park, and operates as a mid-sized, multidisciplinary research organization.

In 2023, Astex announced a collaboration with Merck to develop small-molecule candidates targeting the p53 tumor suppressor protein for cancer treatment, illustrating its ongoing engagement in external partnerships. The company sits within the biotechnology research sector as a collaborative partner for pharmaceutical companies pursuing innovative drug-discovery approaches in oncology and CNS disorders.

Sign up for free to view info

Company overview Employee directory